9. The incidence of pressure ulcers increased to 5/1000 patients in the last quarter in your hospital. You are planning to implement an intervention to decrease the incidence. a. Do you

  1. Read the Brexanolone study by Meltzer-Brody et al. (2018). Answer the following questions:

    1. The outcome measure in this study is post- partum depression. The authors used the HAMD scale to measure depression. What factors did they consider in choosing this scale?

    2. On page 62 – they also describe multiple other tests to measure secondary efficacy outcomes. Why did they do this?

    3. What effect size did they use to calculate the sample?

    4. What was the actual effect size in the study?

    5. A patient on your unit received BRX90 (Study 2)), 1 day ago and is being discharged, accompanied by her husband. What patient education will you provide?

  1. Read the Lefamulin study by XXX Answer the following question:

    1. According to the statistical analysis, the results were evaluated using a 10% non-inferiority margin. Does the data support this hypothesis? Provide at least two study findings to support your answer.


  1. Read the Ubrogepant study by Dodick et al. (2019). Answer the following questions:

    1. Was the sample size calculated using a non-inferiority approach or a superiority approach? Does the data support your answer?

    2. As part of an evidenced based project at work, you are presenting this article to recommend the inclusion of this drug to the hospital’s Pharmacy Formulary. Select 1 Primary Endpoint and 2 secondary endpoints and explain to the members of the committee why they should add this drug to the formulary. Keep your language as simple as possible as not all members had a research background

  1. Read the Tirzepatide study by Frias et al. (2021). Answer the following questions:

    1. You are presenting this article at your unit-based council meeting. 50% of the nurses have a BSN, 5% are pursuing a Masters degree and 45% have an Associates degree. On page 503, the Background of the article is presented. Provide a simple but comprehensive explanation of the background as written here to your audience

    2. Why was the most common TEA nausea?

    3. In your outpatient practice, one of your patients on 10 mg of Tirzepatide for 2 weeks is complaining of nausea. What patient education do you provide to help him to cope with nausea?

    4. How can you convince him to stay on the drug for at least 1 year?

  1. Consider and read the following, and then answer the following questions.

Background: Persons with diagnosed HIV (PWDH) now have longer life expectancy

Aims: Among PWDH aged >/=20 years, in New Jersey, from 2000-2018, 1) Evaluate AAMR/100,000 population by sex, race-ethnicity, and area of prevalence, 2) identify underlying causes of death, and 3) rank the underlying causes of death

Methods: Used Mortality data from the New Jersey Department of Health, Center for Healthcare Quality, and Informatics, from 2000-2018.

The International Classification of Disease, Tenth Revision (ICD-10) codes were used to assign the underlying cause of death.

Population estimates from the 2010 United States Census Bureau, for New Jersey, were used to standardize rates, by age, in four time periods (2000-2004, 2005-2009, 2010-2014, 2015-2018) per 100,000 population.

The proportion of specific diseases was used to rank the top underlying causes of mortality, in each time-period.

Underlying causes of death: cardiac, cancer, diabetes mellitus, renal disease, liver disease, opportunistic illness, pneumonia, respiratory illness, sepsis

High prevalence cities: Jersey City, Paterson, Newark, East Orange, Irvington, Elizabeth, Trenton, Atlantic City, Plainfield, and Camden City.

Results:

Results: Table 1: Demographic Data

 

Characteristic

2000-2004

N (%)

3,751 (42.7)

2005-2009

N (%)

2,509 (28.6)

2010-2014

N (%)

1,622 (18.5)

2015-2018

N (%)

892 (10.2)

Total

8,774

Age

 

 

 

 

 

20-34

424 (11.3)

162 (6.5)

119 (7.3)

63 (7.1)

768 (8.8)

35-44

1,464 (39.0)

714 (28.5)

236 (14.6)

102 (11.4)

2,516 (28.7)

45-54

1,355 (36.1)

1,011 (40.3)

585 (36.1)

209 (23.4)

3,160 (36.0)

55-64

383 (10.2)

478 (19.1)

496 (30.6)

344 (38.6)

1,701 (19.4)

>65

125 (3.4)

144 (5.7)

186 (11.5)

174 (19.5)

629 (7.1)

Sex

 

 

 

 

 

Male

2,471 (65.9)

1,654 (65.9)

1,046 (64.5)

590 (66.1)

5,761 (65.7)

Female

1,280 (34.1)

855 (34.1)

576 (35.5)

302 (33.9)

3,013 (34.3)

Race/Ethnicity

 

 

 

 

 

Black

2,434 (64.9)

1,576 (62.8)

1,047 (64.6)

587 (65.8)

5,644 (64.3)

Hispanic

579 (15.4)

392 (15.6)

264 (16.3)

131 (14.7)

1,366 (15.6)

Other

738 (19.7)

541 (21.6)

311 (19.1)

174 (19.5)

1764 (20.1)

High Prevalence City

 

 

 

 

 

Yes

2,324 (62.0)

1,515 (60.4)

938 (57.8)

484 (54.3)

5,261 (60.0)

No

1,427 (38.0)

994 (39.6)

684 (42.2)

408 (45.7)

3,513 (40.0)

    1. The background of this study is persons with diagnosed HIV (PWDH) now have longer life expectancy. AIMS: Among PWDH aged >/=20 years, in New Jersey, from 2000-2018

    2. Evaluate AAMR/100,000 population by sex, race-ethnicity, and area of prevalence

    3. Summarize findings in Figure 1 below – used to rank the diseases

    1. What advice would you give the planning body at the Department of Health to prevent deaths in this population?

9. The incidence of pressure ulcers increased to 5/1000 patients in the last quarter in your hospital. You are planning to implement an intervention to decrease the incidence.

a. Do you do a clin\ical trial or EBP intervention.

b. What steps will you take before you implement the intervention?

10. A nurse in ICU noted that relationships between residents and nurses are strained. She wants to improve interprofessional collaboration on the unit

a. Should she do a clinical trial or EBP intervention

b. What steps do you advise before implementing an intervention